# LIXTE: Transforming cancer treatment with PP2A inhibitors

> Lixte Biotechnology Holdings, Inc\. \(Nasdaq: LIXT\) is a clinical\-stage pharmaceutical company developing a new class of oncology treatments and cancer therapies called PP2A inhibitors\.

Generated by Yoast SEO v28.6, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [Our Approach](https://lixte.com/)
- [Team](https://lixte.com/team/)
- [Programs](https://lixte.com/programs/)
- [Scientific References](https://lixte.com/science/scientific-references/)
- [Science](https://lixte.com/science/)

## Categories
- [Articles](https://lixte.com/category/articles/)
- [Video](https://lixte.com/category/video/)
- [Podcast](https://lixte.com/category/podcast/)

## Optional
- [Sitemap index](https://lixte.com/sitemap_index.xml)